Regeneron Highlights Hematology Program Data at ASH
Regeneron said it highlighted new data across its malignant and classical hematology programs at the American Society of Hematology meeting. The body begins to reference a trial analysis but is truncated.
Story updates
12:08:23 PM UTC
SquawkNews
Primary analysis from a potentially pivotal trial of Ordspono (odronextamab) in patients with R/R ma